美国ChemDiv  
ChemDiv公司已经有20年的历史，目前在全球拥有超过1500名高端客户。占到全球市场份额的40%。公司致力于为药物发现，制药和生物技术发展的合作伙伴提供创新性解决方案；努力让工业和学术研究进行更好的融合，为威胁生命的疾病带来新的解决方法。公司拥有全球最大的小分子化合物库，除了目前库存的125万种化合物以外，每年以15万种新化合物的速度递增。此次交流对中国科研工作者与国际大型药物筛选公司接触和了解起到了重要作用，一定程度上为今后的科研工作开拓了思路。

ChemDiv is a fully integrated discovery and development Contract Research Organization (CRO) headquartered in San Diego, CA, USA, with subsidiaries in Russia and Ukraine, business and logistics operations around the world. Our organisation collaborates with pharmaceutical and biotech partners by enabling them to accelerate R&D programs to higher value clinical inflection points. One of the industry's most established CROs, ChemDiv offers Integrated Discovery outSource solutions that cover a complete range of disciplines needed to bring a new project in CNS, oncology, inflammation, metabolic, infectious and other diseases from identification of a biological target (protein expression, assay development etc.) to clinical drug candidates (ADME/DMPK, toxicity and safety studies, efficacy models etc.) to Proof of Concept drug candidate (Phase I and II) and to the market. With successful 20 years business record in life sciences and over 500 research associates employed globally, we put forward unique translational capabilities from Research to Clinical Development.

ChemDiv's expertise in rational drug design, synthetic and medicinal chemistry in various therapeutic areas of target classes has allowed it to successfully execute collaborations with leading Pharmaceutical and Biotechnology companies leveraging company's core capabilities in chemistry and biology. We also provide translational research and development support to help bring candidates forward in development through offering a comprehensive package of pre-clinical and clinical services. By applying its strong in-house R&D expertise and a blend of unique business models, ChemDiv is exceptionally positioned to provide its partners with Proof of Concept data in less time and at a fraction of the cost typically seen in the pharmaceutical industry therefore mitigating very high risks associated with the full scale clinical development.